Hematology Consults

Hemolysis

Confirm red-cell destruction, assess marrow compensation, interpret the smear and direct antiglobulin test, distinguish immune from nonimmune causes, and recognize syndromes requiring urgent treatment.

Audience: internal medicine residents Last reviewed: July 2026

Bedside approach

Answer these questions first

Is hemolysis present? Look for a compatible combination of falling hemoglobin, reticulocytosis, increased LDH and indirect bilirubin, reduced haptoglobin, hemoglobinuria, and smear findings.
Is the marrow responding? Review the absolute reticulocyte count and correct the percentage for the severity of anemia.
What does the smear show? Schistocytes, spherocytes, bite cells, agglutination, parasites, and sickled cells can redirect the workup immediately.
Is the process immune? Use the DAT when AIHA, transfusion-related hemolysis, or drug-induced immune destruction is plausible.
Are platelets also low? Hemolysis with thrombocytopenia raises concern for TTP/TMA, DIC, severe infection, or mechanical destruction.
Is transfusion urgent? Compatibility testing may be complex in AIHA, but transfusion decisions are driven by clinical urgency. [1]

Urgent escalation

  • Hemodynamic instability, ischemia, syncope, or severe hypoxemia
  • Rapid or ongoing hemoglobin decline
  • Thrombocytopenia with schistocytes and biochemical hemolysis
  • Neurologic, renal, or cardiac injury suggesting TMA
  • Hemolysis during or shortly after transfusion
  • Hemoglobinuria with acute kidney injury
  • Severe anemia with an inadequate reticulocyte response
  • Suspected malaria, babesiosis, or clostridial sepsis

1. Confirm hemolysis

Test Supporting finding Interpretation and limitations
Hemoglobin trend Unexplained decline Exclude bleeding, dilution, phlebotomy, laboratory error, and impaired production.
Reticulocytes Increased absolute or corrected response May be blunted by nutrient deficiency, renal dysfunction, infection, marrow disease, chemotherapy, parvovirus, or very early hemolysis.
LDH Increased Nonspecific; may rise with tissue injury, liver disease, malignancy, ineffective erythropoiesis, or specimen hemolysis.
Indirect bilirubin Increased May remain normal in mild hemolysis and may be altered by liver disease.
Haptoglobin Reduced or undetectable May be low in liver disease and falsely reassuring during inflammation because it is an acute-phase reactant.
Urinalysis Heme positive with few or no RBCs Suggests hemoglobinuria, although myoglobin can produce the same dipstick pattern.
DAT IgG and/or complement attached to RBCs Supports immune coating but does not independently establish active autoimmune hemolysis.

Practical initial orders

  • CBC with differential and prior-count review
  • Absolute reticulocyte count
  • Peripheral smear
  • LDH
  • Total and direct bilirubin
  • Haptoglobin
  • Creatinine and urinalysis
  • DAT with IgG and C3 characterization when available
  • PT/INR, aPTT, fibrinogen, and D-dimer if DIC is possible
  • Type and screen if transfusion may be required

Interactive tool

Reticulocyte-response calculator

Corrected reticulocyte percentage

Enter the reticulocyte percentage and hematocrit.

Corrected retic = retic % × patient hematocrit ÷ reference hematocrit.

Reticulocyte production index

Enter the reticulocyte percentage and hematocrit.

RPI = corrected reticulocyte percentage ÷ maturation factor.

2. Peripheral smear patterns

Finding Important associations Immediate implications
Schistocytes TTP/TMA, DIC, mechanical valve or device, severe hypertension Review platelets, creatinine, neurologic findings, coagulation tests, blood pressure, and device function.
Spherocytes Warm AIHA or hereditary spherocytosis Interpret with DAT, family history, splenomegaly, and membrane testing when indicated.
Bite or blister cells Oxidant injury, including G6PD deficiency Review medications, food exposures, chemicals, and infection.
RBC agglutination Cold-antibody-mediated hemolysis Correlate with C3-positive DAT, temperature-related symptoms, and cold agglutinin testing.
Parasites Malaria or babesiosis Obtain urgent confirmatory testing based on exposure and local protocols.

Schistocytes plus thrombocytopenia

Treat this pattern as a possible thrombotic microangiopathy until a more convincing explanation is established. Obtain ADAMTS13 before plasma therapy when feasible, but do not delay urgent treatment of strongly suspected TTP.

3. Direct antiglobulin test

DAT pattern Common interpretation Important caveats
IgG positive, C3 negative Often a warm-antibody pattern Consider warm AIHA, drug-associated antibody, and transfusion-related alloantibody.
IgG positive, C3 positive Warm AIHA with complement fixation or mixed pattern Ask the transfusion service to characterize the serology.
IgG negative, C3 positive Cold-antibody process is more likely Consider cold agglutinin disease and paroxysmal cold hemoglobinuria.
DAT negative Immune hemolysis is less likely but not excluded Consider enhanced testing if suspicion remains high, while reassessing nonimmune causes.
A positive DAT may occur after transfusion, with certain medications, after passive antibody exposure, or without clinically significant hemolysis. Do not diagnose AIHA from the DAT alone.

4. Autoimmune hemolytic anemia

Warm AIHA

  • Corticosteroids remain standard initial therapy for most symptomatic warm AIHA. [2]
  • A common initial regimen is prednisone approximately 1 mg/kg/day, followed by a gradual, response-directed taper.
  • Consider earlier rituximab for severe disease, inadequate response, relapse, or steroid dependence.
  • Evaluate for CLL, lymphoma, autoimmune disease, infection, immunodeficiency, malignancy, and implicated medications.
  • Assess thrombotic risk because active AIHA is associated with venous thromboembolism.

Cold agglutinin disease

  • Maintain warmth and avoid cold exposure.
  • Use warmed fluids and blood when appropriate.
  • Evaluate for an underlying clonal or secondary disorder.
  • Corticosteroids are considerably less effective than in warm AIHA and should not be reflexively used as chronic therapy. [3]
  • B-cell-directed or complement-directed therapy may be appropriate under hematology guidance.

5. Transfusion in AIHA and hemolysis

Do not withhold urgently needed RBCs

Broad autoantibody reactivity may make donor units appear incompatible. When anemia is immediately dangerous, communicate the urgency to the transfusion service and provide the safest available units through the emergency pathway. [1]

Suspected acute hemolytic transfusion reaction

  1. Stop the transfusion immediately.
  2. Maintain IV access according to the local reaction protocol.
  3. Assess airway, breathing, circulation, vital signs, and urine output.
  4. Recheck patient and product identification.
  5. Notify the blood bank or transfusion service immediately.
  6. Send the bag, tubing, blood specimens, urine, cultures, and other tests as directed.
  7. Treat shock, DIC, and kidney injury through the appropriate pathway.
Do not restart the implicated unit unless explicitly cleared under institutional policy. [4]

6. Resident summary

  1. Confirm hemolysis using multiple concordant findings.
  2. Correct the reticulocyte percentage for anemia.
  3. Use the smear to narrow the cause.
  4. Treat hemolysis plus thrombocytopenia as possible TMA or DIC until clarified.
  5. A positive DAT does not independently diagnose active AIHA.
  6. Warm and cold AIHA require different treatment approaches.
  7. Do not delay urgent RBC transfusion solely because compatibility testing is complex.

7. Knowledge check

Question 1

A patient has hemoglobin 7.2 g/dL, reticulocytes 4%, and hematocrit 22%. Why can the raw reticulocyte percentage be misleading?

Question 2

A patient has thrombocytopenia, schistocytes, increased LDH, undetectable haptoglobin, and confusion. What is the priority?

Question 3

A patient has a positive DAT but normal hemoglobin, LDH, bilirubin, haptoglobin, and reticulocytes. What is the best interpretation?

References

  1. Johnson ST, Puca KE. Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory. ASH Education Program. 2022. Open article
  2. Kuter DJ. Warm autoimmune hemolytic anemia and the best treatment strategies. ASH Education Program. 2022. Open article
  3. Despotovic JMD, et al. Cold AIHA and the best treatment strategies. ASH Education Program. 2022. Open article
  4. Centers for Disease Control and Prevention. NHSN Hemovigilance Module Protocol. Open protocol

Educational disclaimer

This guide is intended for clinician education and does not replace institutional protocols, hematology consultation, transfusion-service guidance, or individualized clinical judgment. Severe hemolysis, suspected TTP, and transfusion reactions require urgent local escalation.